Search Results
59 items found for "Wilms tumor"
- Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of...
September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model antibody atezolizumab and nab-paclitaxel has shown clinical activity in advanced TNBC with PD-L1-positive tumor-infiltrating As tumor-associated macrophages (TAMs) serve as major contributors to the immuno-suppressive tumor microenvironment We show that through proper calibration, the model captures the macrophage heterogeneity in the tumor
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors
- Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR...
Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in tumor live-imaging modalities, and displayed high efficiency when used to label complex 3D cellular systems such as tumor A2BAR as a potential pharmacological tool in CRC, using selective antagonists, finding a reduction in tumor
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
Azodopa is the first photoswitchable dopamine agonist with demonstrated efficacy in wild-type animals
- PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
PAR4 emerges as a potent oncogene, capable of inducing tumor generation. attenuates PAR2&4-Akt/PKB associations; PAR4 instigated Matrigel invasion and migration in vitro and tumor We propose that Pc(4-4) may serve as a powerful drug not only toward PAR-expressing tumors but also for treating EGFR/erbB-expressing tumors in cases of resistance to traditional therapies.
- CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma via...
(CCR9), an organ-specific chemokine receptor, interacts with its exclusive ligand CCL25 to promote tumor Immunohistochemistry staining and RT–qPCR analyses were performed to detect the correlation of CCR9 expression and tumor The effect of CCL25 on the development of SACC in vivo was examined by a xenograft tumor model in nude
- MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?
Additionally, CXCR4 is expressed by tumor cells in blood malignancies and solid tumors."
- PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer
Indeed, EZH2 is found to be directly correlated with high PAR4-driven tumors, and is abundantly expressed in large tumors, whereas very little to almost none is expressed in small tumors.
- Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs)...
Gene Expression Omnibus (GEO) data, our analysis revealed that (a) RGS20 was strongly upregulated in tumor RGS20 was strongly associated with some important clinical parameters such as alpha-fetoprotein and tumor serous cystadenocarcinoma: p = 0.048); (d) RGS20 was found to be significantly associated with some tumor-related
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors than effectors, mutations in different receptors could perturb signaling similarly so as to favor a tumor We hypothesized that somatic mutations in tumor samples may not be enriched within a single gene but that recurrent impactful oncogenic mutations perturb different GPCRs to subvert signaling and promote tumor
- Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin ...
In CRPC xenografts, antagonizing AVPR2, AVPR1A, or both significantly reduced CRPC tumor growth as well as decreased on-target markers of tumor burden.
- Chemokine receptor-targeted drug discovery: progress and challenges
diseases (Proudfoot 2002), and in recent years attention has increasingly focused on cancer, where tumors chemokine system to provide growth and survival signals, establish and maintain an immunosuppressive tumor Redundancy can be exemplified by the tumor infiltration of Treg cells which can be driven directly by
- Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas ...
Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve identified as a potential biomarker of favorable overall survival in isocitrate dehydrogenase (IDH) wild-type OR5D18 (mouse Olfr1155) was the most frequently mutated OR gene, and OR5AR1 (mouse Olfr1019) showed IDH wild-type-specific
- GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...
potential correlation between G-protein-coupled receptor-associated sorting protein 1 (GASP1) and breast tumorigenesis expressed in breast cancers, and patients harboring altered GASP1 showed a worse prognosis than those with wild-type cells, such as inhibition of cell proliferation, colony formation, migration, invasion and xenograft tumor signaling pathways such as NF-κB, PI3K/AKT, and MAPK/ERK pathways given their critical roles in breast tumorigenesis
- Neurotransmitters: Potential Targets in Glioblastoma
September 2022 "For decades, glioblastoma multiforme (GBM), a type of the most lethal brain tumor, has
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
Somatostatin receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent somatostatin receptor type 2 (SST2) and 5 (SST5) and regulates their expression and signaling in pituitary tumoral
- The expression and clinical significance of GPR39 in colon cancer
Materials: In our study, we compared GPR39 expression between colon cancers and tumor-adjacent tissues
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors
- Odorant receptors – a bit of smell for drug discovery
with transcriptomic analysis revealing that while the majority of cancer cells express multiple ORs, tumor directed towards an OR could either drive receptor inactivation or activation of the receptor to destroy tumor The chimeric antigen receptor T cell therapy could also be a way to target tumor cells expressing ectopic
- The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?
In this review, we discuss both the ‘friend’ and ‘foe’ features of TGR5 by summarizing its tumor-suppressing
- A2B Adenosine Receptor Enhances Chemoresistance of Glioblastoma Stem-Like Cells under Hypoxia: New..
Insights into MRP3 Transporter Function "Glioblastoma is the most common and aggressive primary brain tumor
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors
- High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and...
the worse survival in patients with lymph node metastasis, TNM stage III as well as nuclear grade G3 tumors
- 📰 GPCR Weekly News
GPR4 in the pH-dependent migration of melanoma cells in the tumor microenvironment. dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors
- G-protein-coupled receptors as therapeutic targets for glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. this, the prognosis remains poor, with an impacted quality of life during treatment coupled with brain tumour
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
GPCRs in Oncology and Immunology G protein-coupled receptor-mediated signaling of immunomodulation in tumor
- All Aboard the GPCR Express: Your Weekly Update is here! Oct 14-20, 2024
Convergent substitutions and recurrent gene loss in sauropsids Noval insights and therapeutic strategies for tumor-induced